Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Airways to Arteries: Dissecting the Inflammatory Mechanisms of Pulmonary Vascular Remodeling in a Murine Model of Chronic Airway Inflammation.

Biomedicines·2026
Same author

A brain-penetrant chimeric protein combines direct glioma targeting with myeloid cell-mediated immune reprogramming.

Journal of translational medicine·2026
Same author

Interference of Large Clostridial Glucosyltransferases with the Endolysosomal Pathway: Toxin-Induced Imbalance of Early Endosomes, Functional Lysosomes and Autophagosomes.

Toxins·2026
Same author

FLASH radiotherapy preserves systemic and tissue homeostasis while maintaining antitumor efficacy.

BMC medicine·2026
Same author

Anthrax Toxin: A Pioneer of Targeted Protein Toxins.

Toxins·2025
Same author

Injection of Affibodies by a Self-Organizing Bacterial Syringe to Interfere with Intracellular Signaling.

Toxins·2025

Related Experiment Video

Updated: Nov 10, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.2K

CTX-CNF1 Recombinant Protein Selectively Targets Glioma Cells In Vivo.

Eleonora Vannini1,2, Elisabetta Mori3, Elena Tantillo1

  • 1Neuroscience Institute, National Research Council (CNR), via G. Moruzzi 1, 56124 Pisa, Italy.

Toxins
|April 3, 2021
PubMed
Summary

A new chimeric protein, CTX-CNF1, effectively targets glioma cells and crosses the blood-brain barrier. This novel approach shows potential for treating gliomas by reducing tumor mass and increasing survival rates.

Keywords:
brain tumorchlorotoxincytotoxic necrotizing factor type 1drug deliverydrug discoveryglioblastomagliomarecombinant protein production

More Related Videos

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
09:17

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma

Published on: January 15, 2016

15.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K

Related Experiment Videos

Last Updated: Nov 10, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.2K
Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
09:17

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma

Published on: January 15, 2016

15.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K

Area of Science:

  • Neuro-oncology
  • Biotechnology
  • Protein engineering

Background:

  • Current glioma treatments lack tumor selectivity, necessitating novel therapeutic strategies.
  • Bacterial cytotoxic necrotizing factor 1 (CNF1) shows promise in reducing glioma mass and improving survival but cannot cross the blood-brain barrier (BBB).

Purpose of the Study:

  • To develop a non-invasive method for delivering CNF1 across the BBB for glioma treatment.
  • To create a chimeric protein, CTX-CNF1, by conjugating CNF1 with chlorotoxin (CTX).

Main Methods:

  • Conjugation of CNF1 with chlorotoxin (CTX) to create the chimeric protein CTX-CNF1.
  • Systemic administration of CTX-CNF1 in glioma-bearing mice models.
  • Evaluation of CTX-CNF1's ability to target glioma cells and cross the BBB.

Main Results:

  • CTX-CNF1 successfully crossed the BBB and targeted glioma cells after systemic administration.
  • CTX-CNF1 significantly reduced tumoral mass and prolonged survival in glioma-bearing mice.
  • Peritumoral neural tissue protection from dysfunction was observed.

Conclusions:

  • CTX-CNF1 represents a promising novel therapeutic tool for glioma treatment.
  • The chimeric protein enables non-invasive administration and effective targeting of gliomas.
  • This approach overcomes the BBB limitation of native CNF1 for potential clinical translation.